Robert N. Cavanaugh, President of Accolade, Inc. (NASDAQ:ACCD), recently engaged in stock transactions involving the company's common stock. The transactions come as the company's shares trade near their 52-week low of $3.08, having declined over 71% year-to-date. On December 17, Cavanaugh sold 156 shares at an average price of $3.432 per share, amounting to a total value of $535. This sale was conducted to cover tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs). Cavanaugh's transactions also included the conversion of RSUs into common stock, adding 510 shares to his holdings on December 16. Following these transactions, Cavanaugh holds 213,295 shares directly in the $263 million market cap company. According to InvestingPro analysis, Accolade appears undervalued at current levels, with additional insights available in the comprehensive Pro Research Report covering this and 1,400+ other US stocks.
In other recent news, Accolade Inc (NASDAQ:ACCD). has been garnering attention from analyst firms due to its financial performance and future potential. Wells Fargo (NYSE:WFC) adjusted Accolade's price target to $6.00, reflecting concerns over delayed deal closures, while maintaining an Equal Weight rating. Stephens and Canaccord Genuity (TSX:CF) also revised their price targets for Accolade to $8.00 and $7.00 respectively, but kept their Overweight and Buy ratings. Truist Securities and BofA Securities followed suit, reducing their price targets to $7.50 and $5.75 while maintaining Buy ratings.
Accolade's recent financial results exceeded expectations with a Q2 2025 revenue of $106.4 million and an outperforming adjusted EBITDA. The company also confirmed its FY 2025 revenue guidance between $460 million to $475 million, and projected a positive adjusted EBITDA of $15 million to $20 million. Despite anticipation of slower revenue growth in FY 2026 due to staggered launches, analysts remain confident in Accolade's ability to meet performance guarantees and secure new business.
Accolade's management has expressed optimism about a strong pipeline diversified across employers, health plans, and government segments. Noteworthy developments include Accolade's competitive edge in the expert medical opinion product market and its successful management of marketing expenses. These recent developments reflect the company's strategic direction and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.